Business news for the stock market
Leverkusen, Germany (pta023/01.07.2024/10:55) - For the 11th consecutive year, Biofrontera hosted a CME-certified training event for dermatologists, where distinguished experts provided an overview of current and future developments in the field of Photodynamic Therapy (PDT). This year's event, titled "Photodynamic Therapy (PDT) at the Cutting Edge," took place in Berlin.
The event featured a wide range of topics, including general workshops for PDT beginners and advanced sessions for experienced practitioners. A total of 13 experts from across Germany highlighted various aspects of PDT, offering participants a comprehensive overview of current developments and practical applications. Special attention was paid to daylight PDT and therapy with artificial daylight. Ameluz® received expanded approval for the latter treatment option just a few months ago. This year, as in previous years, the participating experts emphasized the necessity of early, sustainable, and field-directed therapy for actinic keratoses (AK) to reduce the risk of progression to solid skin tumors.
Participation in CME-certified training is especially valuable for dermatologists, as it allows them to continuously expand their expertise and stay informed about the latest developments and innovative treatment methods.
"Biofrontera is one of the leading companies in the field of photodynamic therapy and is continuously committed to its further development. Through events like this training session, we promote the exchange of knowledge and continuing education in the medical community. In the German PDT market for the treatment of AK, Biofrontera is the market leader with over 60% and records double-digit growth rates in terms of revenue. With sales units in Spain and the United Kingdom, Biofrontera is also striving for PDT market leadership in these countries. Especially for Spain, this is a set goal for 2024. Following the spin-off of the US market, Biofrontera is focusing more on expanding its European marketing activities, both by intensifying efforts in existing markets and by exploring new territories," commented Pilar de la Huerta, CFO of Biofrontera AG.
(end)
emitter: Biofrontera AG
address: Hemmelrather Weg 201, 51377 Leverkusen
country: Germany
contact person: Investor Relations
phone: +49 (0) 214 87 63 20
e-mail: ir@biofrontera.com
website: www.biofrontera.com
ISIN(s): DE000A4BGGM7 (share)
stock exchanges: regulated market in Dusseldorf, Frankfurt; free market in Munich, free market in Stuttgart; open market in Berlin, Tradegate